Foamix Pharmaceuticals announced the U.S. Patent and Trademark Office has issued U.S. Patent No. 10,463,742, reciting waterless compositions comprising a retinoid and a tetracycline antibiotic, as well as methods of using those compositions in treating dermatological disorders. This newly issued patent, which expires in 2030, is the latest U.S. patent to be issued to Foamix in connection with Foamix’s drug development programs for treating acne vulgaris.
“We are delighted with the addition of this new patent, which provides additional coverage for our combination product candidate, FCD105, a topical foam for moderate-to-severe acne with a retinoid and minocycline,” said David Domzalski, Chief Executive Officer of Foamix. “The patent demonstrates our continued development of our patent portfolio and our commitment to innovation in dermatology.”
Subscribe to our e-Newsletters
Stay up to date with the latest news, articles, and events. Plus, get special offers
from American Pharmaceutical Review – all delivered right to your inbox! Sign up now!